GlassScriptPhysician profile
Adam Isaac
NPI 1861050023
$1,511.82
in general payments reported to CMS, 2019-2025
18 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.96 · 2024: $474 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.62 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $290.18 | 2024-2025 | Airsupra, Fasenra, Evusheld |
| Glaxosmithkline, LLC. | $233.66 | 2024-2025 | Nucala, Trelegy Ellipta |
| Pfizer INC. | $140.07 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $139.74 | 2024-2025 | Zerbaxa, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.99 | 2024-2025 | Ofev, Jascayd |
| Ani Pharmaceuticals, INC. | $94.74 | 2025 | Purified Cortrophin Gel |
| Ambu INC. | $70.59 | 2025 | |
| La Jolla Pharmaceutical Company | $68.59 | 2024-2025 | Giapreza |
| Mallinckrodt Hospital Products INC. | $65.41 | 2024-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $49.70 | 2024-2025 | Dupixent |
| Genzyme Corporation | $44.23 | 2024 | |
| United Therapeutics Corporation | $37.47 | 2025 | Tyvaso |
| Grifols USA, LLC | $32.11 | 2025 | Prolastin-C Liquid |
| Insmed, INC. | $30.16 | 2024 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $28.41 | 2024-2025 | Glassia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $21.48 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $18.33 | 2025 | Opsumit, Uptravi |
| Organon LLC | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Isaac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.